{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:12:52Z","timestamp":1792257172510,"version":"4.4.0"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"publisher","award":["MRC-01-19-331"],"award-info":[{"award-number":["MRC-01-19-331"]}],"id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Echinocandins are recommended as an initial treatment for invasive candidiasis. Although safety and efficacy profiles of both anidulafungin and caspofungin are well established, direct head-to-head comparisons have not been reported before.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Compare efficacy and safety of anidulafungin versus caspofungin among patients with invasive candidiasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Adult patients with invasive candidiasis who were treated with either anidulafungin or caspofungin for \u2a7e5\u2009days were retrospectively reviewed over a period of 6 years. The primary endpoint was global response, defined as clinical and microbiological success at the end of treatment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 223 patients who received either anidulafungin (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009176) or caspofungin (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200947) were initially included. Propensity score matching (based on age, malignancy, level of care, presence of candidemia, and other factors) was performed to improve comparability of the two groups. As a result, 32 patients in the caspofungin arm and 79 patients in the anidulafungin arm were included in the final analysis. Around three-quarters of the cohort had candidemia, and the most common isolated\n                      <jats:italic>Candida<\/jats:italic>\n                      species were\n                      <jats:italic>C. albicans<\/jats:italic>\n                      and\n                      <jats:italic>C. glabrata<\/jats:italic>\n                      . Response rates were comparable between both groups, with the primary outcome of global response showing no significant difference (56.3% for the caspofungin group vs 63.3% for anidulafungin,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.490). Similarly, no differences between the two groups were observed in terms of 90-day all-cause mortality (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.672) or any other secondary endpoints.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our data suggest that anidulafungin and caspofungin have comparable global response among patients with invasive candidiasis. Additionally, both studied echinocandins showed no significant difference in 90-day all-cause mortality. However, due to the limited sample size, larger studies are needed to confirm these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20499361251344777","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T07:21:41Z","timestamp":1754119301000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7824-3203","authenticated-orcid":false,"given":"Reem Hasan","family":"Elajez","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Bakdach","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Al Balushi","sequence":"additional","affiliation":[{"name":"Epidemiology Section, Communicable Disease Centre, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Zaqout","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Communicable Disease Centre, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rand","family":"Alattar","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Communicable Disease Centre, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Awouda","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Communicable Disease Centre, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godwin","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Al-Wali","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar"},{"name":"Biomedical Research Center, Qatar University, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Alsoub","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Communicable Disease Centre, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/376906"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc10114"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1315399"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01901-07"},{"key":"e_1_3_4_6_2","unstructured":"U.S. Food and Drug Administration. [Internet]. https:\/\/www.fda.gov\/media\/164668\/download (accessed 15 September 2024)."},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1029916"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2013.04.006"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1194"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12039"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00749-7"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006297227"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-8-23"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1143-1"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1825-3"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/520980"},{"key":"e_1_3_4_17_2","unstructured":"Common terminology criteria for adverse events version 5 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf (2017 accessed 23 January 2024)."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-261"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021585"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.3.369"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-009-1511-7"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12831"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01475-8"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu407"}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361251344777","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20499361251344777","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361251344777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:01:26Z","timestamp":1777593686000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20499361251344777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":23,"alternative-id":["10.1177\/20499361251344777"],"URL":"https:\/\/doi.org\/10.1177\/20499361251344777","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"20499361251344777"}}